Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kim Margolin

Showing results (11-20 of 96) with videos related to

Pageof 10
Sort By:
Journal of the National Comprehensive Cancer Network : JNCCN|October 10, 2009
Management of advanced germ cell cancer in patients with unfavorable prognosisKim Margolin
Hematology/Oncology Clinics of North America|June 2, 2014
Introduction to the role of the immune system in melanomaKim Margolin
JAMA Oncology|June 1, 2016
Treatment of Renal Cell Cancer With Programmed Cell Death 1 Blockade: How Much Is Enough?Kim Margolin
Current Oncology Reports|December 6, 2001
Inhibition of vascular endothelial growth factor in the treatment of solid tumorsKim Margolin
Current Oncology Reports|August 5, 2004
Treatment of advanced melanoma with temozolomide: IKim Margolin
Current Oncology Reports|August 5, 2004
Treatment of advanced melanoma with temozolomide: IIKim Margolin
Current Oncology Reports|September 23, 2011
Treatment of advanced melanoma with immunological checkpoint blockKim Margolin
Current Oncology Reports|September 21, 2011
Adoptive T-cell therapy of melanoma using designer T-cell receptorsKim Margolin
Cancer|August 18, 2016
Disparate clinical activity of PD-1 blockade in melanoma subtypes: Know thy enemy!Shailender Bhatia, Kim Margolin
Current Oncology Reports|August 11, 2012
Tumor-infiltrating lymphocytes in melanomaSylvia Lee, Kim Margolin
Pageof 10

Showing results (11-20 of 96) with videos related to

Sort By:
Pageof 10
Journal of the National Comprehensive Cancer Network : JNCCN|October 10, 2009
Management of advanced germ cell cancer in patients with unfavorable prognosisKim Margolin
Hematology/Oncology Clinics of North America|June 2, 2014
Introduction to the role of the immune system in melanomaKim Margolin
JAMA Oncology|June 1, 2016
Treatment of Renal Cell Cancer With Programmed Cell Death 1 Blockade: How Much Is Enough?Kim Margolin
Current Oncology Reports|December 6, 2001
Inhibition of vascular endothelial growth factor in the treatment of solid tumorsKim Margolin
Current Oncology Reports|August 5, 2004
Treatment of advanced melanoma with temozolomide: IKim Margolin
Current Oncology Reports|August 5, 2004
Treatment of advanced melanoma with temozolomide: IIKim Margolin
Current Oncology Reports|September 23, 2011
Treatment of advanced melanoma with immunological checkpoint blockKim Margolin
Current Oncology Reports|September 21, 2011
Adoptive T-cell therapy of melanoma using designer T-cell receptorsKim Margolin
Cancer|August 18, 2016
Disparate clinical activity of PD-1 blockade in melanoma subtypes: Know thy enemy!Shailender Bhatia, Kim Margolin
Current Oncology Reports|August 11, 2012
Tumor-infiltrating lymphocytes in melanomaSylvia Lee, Kim Margolin
Pageof 10